Biograph首项美国研究称AI分析CT发现42.9%无症状低风险成人有冠状动脉炎症

Biograph, the world’s most advanced preventive health and diagnostics clinic, today announced the completion of its first U.S. study using Caristo Diagnostics’ CaRi-Heart® technology evaluating AI-powered coronary inflammation detection in asymptomatic, low-risk individuals. The research revealed that coronary inflammation is widespread among asymptomatic adults without known heart disease – and is undetected by standard blood tests and other traditional cardiovascular risk factors.

The study, available to clinically eligible Biograph Black tier members, combined Biograph’s advanced diagnostics – including high-resolution coronary computed tomography angiography  (CCTA) imaging and cardiometabolic profiling – with Caristo’s CaRi-Heart and CaRi-Plaque® technologies*. This collaborative methodology enabled researchers to assess the prevalence of coronary inflammation using the AI-enabled CaRi-Heart technology to determine cardiovascular risk in individuals who may otherwise appear low risk through traditional screening.

The study found that coronary inflammation is common (42.9%) in asymptomatic, low-risk adults and frequently occurs without any plaque buildup or blockage. Specifically, 42.9% of participants exhibited elevated inflammation with 17.9% of participants exhibiting very high inflammation in at least one major heart artery. The results also suggest a potential limitation in standard assessment: About 47% of participants with no detectable coronary plaque exhibited elevated coronary perivascular inflammation. By evaluating coronary inflammation alongside traditional imaging assessment of plaque burden and stenosis, we get a more complete picture of cardiovascular risk..

Importantly, routine bloodwork and clinical tools – including cholesterol markers (ApoB, non-HDL-C), blood sugar (HbA1c), systemic inflammation (hs-CRP), and a widely used cardiovascular risk calculator (AHA PREVENT-ASCVD) – showed no correlation with the presence of coronary inflammation and failed to identify which patients had inflamed arteries. These results reinforce Biograph’s core philosophy: standalone bloodwork and isolated metrics do not tell the full story.  By directly analyzing the biology of the tissue surrounding the coronary arteries, this non-invasive AI technology uncovers potential cardiovascular risk years before the onset of irreversible heart disease.

"Coronary heart disease, whether plaque accumulation or arterial stenosis, is likely a late consequence of an active inflammatory process in the vessel wall. What is striking about our findings is that more than 42% of asymptomatic, conventionally low-risk adults had elevated coronary inflammation, and many individuals with the highest inflammatory levels had completely normal coronary anatomy on CT. Crucially, no routine blood biomarker, lipid metric, or clinical risk score could identify these individuals with inflamed coronary arteries. This study suggests we may be identifying an upstream phase of disease and a window for proactive intervention. More research is needed to validate this finding and establish the prognostic value and benefit of care directed at coronary perivascular inflammation."

对 Biograph 而言，这项研究的完成体现了其更广泛的使命：通过全面诊断、临床解读以及对长期健康风险的更早洞察，推动主动、个性化医疗。如需审阅临床研究手稿，读者可在此访问已发表的预印本。

*CaRi-Heart® 已获得美国食品药品监督管理局（FDA）的 De Novo 营销授权，是首个且唯一能够通过常规冠状动脉 CT 造影（CCTA）量化冠状动脉炎症的解决方案。CaRi-Plaque® 已获得美国 FDA 的上市许可，可利用人工智能辅助分析冠状动脉斑块和狭窄，并通过评估定量斑块来补充 CaRi-Heart。

Biograph

Biograph 致力于推动人类健康寿命和寿命取得实质性进步。我们的目标不只是帮助你活得更久，而是让你活着的每一年都尽可能美好。因为你生活的品质与生活的时长同样重要。我们坚持以人为本的设计，打造独一无二的临床设施，突破行业惯例。我们承诺在每位会员的整个 Biograph 旅程中为其提供卓越服务。我们持续将最新研究融入我们的方法体系，以始终站在医学前沿。